The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication ...
The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression. Here's what ...
The TGA has issued a requirement for new warnings to be provided with the drug montelukast, commonly used to treat asthma and ...
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
The newly FDA-approved nasal spray called Spravato is being manufactured by Johnson & Johnson's and is a standalone treatment ...
FDA approves Johnson & Johnson's Spravato nasal spray as a monotherapy for major depressive disorder, showing superior ...